Efficacy and safety of dual blockade of the renin-angiotensin-aldosterone system in diabetic kidney disease: A meta-analysis
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Introduction Current guidelines recommend renin-angiotensin-aldosterone system (RAAS) inhibitors in the treatment of diabetic kidney disease (DKD). However, evidence suggests that the combined use of RAAS blockers may be associated with increased rates of adverse events. Objectives Our objective was to examine the efficacy and safety of dual blockade of the RAAS in patients with DKD. Methods This was a systematic review and meta-analysis of randomized controlled trials (RCTs) published between January 1990 and January 2018 sourced via the PubMed, EMBASE, and Cochrane Library databases. RCTs were included if they investigated the efficacy and safety of dual blockade therapy compared with monotherapy in patients with DKD. Random effects models were used in meta-analysis to account for heterogeneities in effect sizes across the reviewed studies. Analyses were stratified by blood pressure and albuminuria. We further conducted subgroup analyses by considering various combinations of RAAS inhibitors. Results Based on 42 RCTs with 14,576 patients, dual RAAS blockade therapy was associated with significant decreases in blood pressure, albuminuria, and proteinuria. However, dual therapy was not superior to monotherapy in terms of reductions in all-cause mortality, cardiovascular mortality, or progression to end-stage renal disease (ESRD). Significant increases in serum potassium and rates of hyperkalemia and hypotension were more common in patients treated with dual therapy. However,…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They also have reported advantage over other treatments in reducing the risk of new-onset T2D in elderly persons.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [255]
Citations
Cites
1 retracted
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216 · cited 1×
“As of 2010, an estimated 284 million people had diabetes worldwide, and this number is expected to reach 438 million by 2030 [1].”
BackgroundReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220 · cited 1×
“Diabetes mellitus had to have been diagnosed according to American Diabetes Association 1997 and World Health Organization 1999 guidelines [12, 13].”
MethodAssessing heterogeneity in meta-analysis: Q statistic or I² index?
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.193 · Cited by 4,256
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589 · cited 3×
“Furthermore, we found no significant increase in creatinine level with dual therapy, which is also in contrast with ONTARGET findings [69].”
MethodResultK/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
(2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.01.019 · Cited by 1,427
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708379 · Cited by 1,098
Mogensen, C. E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R. W., & Cooper, M. E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1440 · Cited by 1,037
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus.
Borch-Johnsen, K., & Kreiner, S. (1987) · BMJ · doi:10.1136/bmj.294.6588.1651 · Cited by 556
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
MacKinnon, M., Shurraw, S., Akbari, A., Knoll, G. A., Jaffey, J., & Clark, H. D. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.04.077 · Cited by 246
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Jacobsen, P., Andersen, S., Rossing, K., Jensen, B. R., & Parving, H.-H. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00940.x · Cited by 226
Rossing, K., Jacobsen, P., Pietraszek, L., & Parving, H.-H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2268 · Cited by 225
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P., & Parving, H. H. (2006) · Kidney International · doi:10.1038/sj.ki.5001580 · Cited by 215
Jacobsen, P., Andersen, S., Jensen, B. R., & Parving, H.-H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000054495.96193.bf · Cited by 209
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
Rossing, K., Christensen, P. K., Jensen, B. R., & Parving, H.-H. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.95 · Cited by 205
van den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Doulton, T. W. R., He, F. J., & MacGregor, G. A. (2005) · Hypertension · doi:10.1161/01.hyp.0000161880.59963.da · Cited by 186
Persson, F., Rossing, P. R., Reinhard, H., Juhl, T. R., Stehouwer, C. D. A., Schalkwijk, C. G., Danser, A. H. J., Boomsma, F., Frandsen, E. L., & Parving, H. (2009) · Diabetes Care · doi:10.2337/dc09-0168 · Cited by 151
Garg, R., Rao, A. D., Baimas-George, M., Hurwitz, S., Foster, C., Shah, R. V., Jerosch-Herold, M., Kwong, R. Y., Di Carli, M. F., & Adler, G. K. (2015) · Diabetes · doi:10.2337/db14-0670 · Cited by 133
Cystatin C, Albuminuria, and Mortality Among Older Adults With Diabetes
de Boer, I. H., Katz, R., Cao, J. J., Fried, L. F., Kestenbaum, B., Mukamal, K., Rifkin, D. E., Sarnak, M. J., Shlipak, M. G., & Siscovick, D. S. (2009) · Diabetes Care · doi:10.2337/dc09-0191 · Cited by 126
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy
Jacobsen, P. K. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.6.1019 · Cited by 125
Jennings, D. L., Kalus, J. S., Coleman, C. I., Manierski, C., & Yee, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02097.x · Cited by 124
Bakris, G. L., Ruilope, L. M., Locatelli, F., Ptaszynska, A., Pieske, B. M., de Champlain, J., Weber, M. A., & Raz, I. (2007) · Kidney International · doi:10.1038/sj.ki.5002455 · Cited by 104
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?
Forclaz, A., Maillard, M. P., Nussberger, J., Brunner, H. R., & Burnier, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000047512.58862.a9 · Cited by 103
Juarez, G. M. F., Luño, J., Barrio, V., de Vinuesa, S. G., Praga, M., Goicoechea, M., Cachofeiro, V., Nieto, J., Vega, F. F., Tato, A., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.011 · Cited by 93
Nielsen, S. E., Persson, F., Frandsen, E., Sugaya, T., Hess, G., Zdunek, D., Shjoedt, K. J., Parving, H., & Rossing, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03585.x · Cited by 86
Catapano, F., Chiodini, P., Nicola, L. D., Minutolo, R., Zamboli, P., Gallo, C., & Conte, G. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.03.008 · Cited by 82
Athyros, V. G., Mikhailidis, D. P., Kakafika, A. I., Τζιόμαλος, Κ., & Karagiannis, A. I. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.5.529 · Cited by 80 · cited 1×
“Because of the so-called escape phenomenon [6], ACEI or ARB therapy alone may not be sufficient to fully block the RAAS.”
BackgroundSusantitaphong, P., Sewaralthahab, K., Balk, E. M., Eiam‐Ong, S., Madias, N. E., & Jaber, B. L. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hps038 · Cited by 79
Şengül, A. M., Altuntaş, Y., Kürklü, A., & Aydın, L. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.06.010 · Cited by 79
Managing diabetes in hemodialysis patients: Observations and recommendations
Shrishrimal, K., Hart, P., & Michota, F. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.09054 · Cited by 78
Song, J. H., Ho, S., Lee, H. J., Lee, S. W., Park, G. H., Lee, S. W., & Kim, M. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi310 · Cited by 73
Saklayen, M. G., Gyebi, L. K., Tasosa, J., & Yap, J. (2008) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31816d78e9 · Cited by 65
Kato, S., Maruyama, S., Makino, H., Wada, J., Ogawa, D., Uzu, T., Araki, H., Koya, D., Kanasaki, K., Oiso, Y., et al. (2015) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1106-2 · Cited by 61
Bomback, A. S., & Toto, R. D. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.138 · Cited by 60
Tütüncü, N. B., Gürlek, A., & Gedik, O. (2001) · Acta Diabetologica · doi:10.1007/s592-001-8073-2 · Cited by 53
Menne, J., Farsang, C., Deák, L., Klebs, S., Meier, M., Handrock, R., Sieder, C., & Haller, H. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e32830508aa · Cited by 52
OGAWA, S., TAKEUCHI, K., MORI, T., NAKO, K., TSUBONO, Y., & ITO, S. (2007) · Hypertension Research · doi:10.1291/hypres.30.325 · Cited by 51
Titan, S., Vieira, J. M., Dominguez, W. V., Barros, R. T., & Zatz, R. (2011) · Clinical Nephrology · doi:10.5414/cn107013 · Cited by 41
Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy
Buren, P. N. V., ADAMS-HUET, B. A., Nguyen, M., Molina, C., & Toto, R. D. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07460713 · Cited by 39
Bakris, G. L., Oparil, S., Purkayastha, D., Yadao, A. M., Alessi, T., & Sowers, J. R. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12032 · Cited by 38
Of fads, fashion, surrogate endpoints and dual RAS blockade
Messerli, F. H., Staessen, J. A., & Zannad, F. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq255 · Cited by 34
Matos, J. P. S., Rodrigues, M., Ismerim, V. L., Boasquevisque, E. M., Genelhu, V. A., & Francischetti, E. A. (2005) · Clinical Nephrology · doi:10.5414/cnp64180 · Cited by 32
Cetinkaya, R., Odabaş, A. R., & Selcuk, Y. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00004.x · Cited by 31
Kim, M. J., Song, J. H., Suh, J. H., Lee, S. W., & Kim, G. A. (2003) · Yonsei Medical Journal · doi:10.3349/ymj.2003.44.3.463 · Cited by 31
Imai, E., Haneda, M., Yamasaki, T., Kobayashi, F., Harada, A., Ito, S., Chan, J. C. N., & Makino, H. (2013) · Hypertension Research · doi:10.1038/hr.2013.86 · Cited by 29
Nakamura, A., Shikata, K., Nakatou, T., Kitamura, T., Kajitani, N., Ogawa, D., & Makino, H. (2012) · Journal of Diabetes Investigation · doi:10.1111/jdi.12004 · Cited by 28
Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P. R., Hollenberg, N. K., & Hans-Henrik, P. (2011) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320311417272 · Cited by 25
Igarashi, M., Hirata, A., Kadomoto, Y., & Tominaga, M. (2006) · Endocrine Journal · doi:10.1507/endocrj.k06-025 · Cited by 23
Atmaca, A. A., & Gedik, O. (2006) · Advances in Therapy · doi:10.1007/bf02850049 · Cited by 22
Makhlough, A., Kashi, Z., Akha, O., Zaboli, E., & Charati, J. Y. (2014) · Nephro-Urology Monthly · doi:10.5812/numonthly.12148 · Cited by 22
Is There Added Value to Adding ARB to ACE Inhibitors in the Management of CKD?
Cohen, D. L., & Townsend, R. R. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008040381 · Cited by 21
Tan, F., Mukherjee, J. J., Lee, K., Lim, P., & Liew, C. F. (2010) · PubMed · Cited by 21
Krairittichai, U., & Chaisuvannarat, V. (2009) · PubMed · Cited by 18
Jacobsen, P. K., & Parving, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09226.x · Cited by 17
The current state of RAAS blockade in the treatment of hypertension and proteinuria
Kalaitzidis, R., & Bakris, G. L. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0063-3 · Cited by 16
Nakamura, T., Ushiyama, C., Osada, S., Takahashi, Y., Shimada, N., Ebihara, I., & Koide, H. (2002) · Clinical and Experimental Nephrology · doi:10.1007/s101570200023 · Cited by 12
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Obesity and chronic kidney disease
Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2022 · Cited by 267
Barrera‐Chimal, J., & Jaisser, F. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13969 · Cited by 174
“angiotensin II receptor blockers (ARBs), captopril, losartan and irbesartan for decreasing albuminuria in patients with DKD.(9) The RAAS plays an important physiological role, but its overactivation is deleterious to the kidney, contributing to a progressive deterioration”
BackgroundMulti-Target Approaches in Metabolic Syndrome
Lillich, F. F., Imig, J. D., & Proschak, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.554961 · Cited by 177
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Metadata
- Authors
- Feng, Y., Huang, R., Kavanagh, J., Li, L., Zeng, X., Li, Y., & Fu, P.
- Affiliations
- West China Hospital of Sichuan University (CN)
- University of Michigan (US)
- West China Medical Center of Sichuan University (CN)
- Corresponding author
- Li, Yi
- Fu, Ping
- Venue
- American Journal of Cardiovascular Drugs
- Published
- 2019-02-09
- Volume
- 19
- Issue
- 3
- Pages
- 259-286
- ISSN
- 1175-3277 (ISSN-L)
- 1179-187X
- OpenAlex
- W2912088793
- Cited by
- 53
- References
- 75
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 11 · 2020: 9 · 2019: 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- diabetic nephropathy, renin-angiotensin-aldosterone system inhibitors, ACE inhibitors, angiotensin receptor blockers, renin inhibitors, hyperkalemia, hypotension, albuminuria, proteinuria, blood pressure control, end-stage renal disease progression, all-cause mortality, cardiovascular mortality, glomerular filtration rate, normotensive subjects
- MeSH terms
- Renin Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Diabetic Nephropathies, Drug Therapy, Combination, Humans, Renin, Renin-Angiotensin System, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.